ArticleOncology letters2026
Prognostic value of the CONUT score in newly diagnosed diffuse large B-cell lymphoma.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma and clinical outcomes remain heterogeneous despite standard R-CHOP therapy. The Controlling Nutritional Status (CONUT) score, an immunonutritional index based on serum albumin, total cholesterol and lymphocyte count, has emerged as a potential prognostic marker in this setting. In this retrospective observational study, the prognostic value of the pre-treatment CONUT score was evaluated in 110 adult patients with newly diagnosed DLBCL treated with standard R-CHOP at a tertiary center between October 2022 and September 2025. Patients were categorized into two groups according to their CONUT scores (<5 vs. ≥5), and baseline clinical characteristics, laboratory parameters and prognostic indices [International Prognostic Index (IPI) and National Comprehensive Cancer Network IPI (NCCN-IPI)] were compared. Overall survival (OS) and progression-free survival (PFS) were analyzed using the Kaplan-Meier method, and independent prognostic factors for OS were identified by Cox regression analysis. A CONUT score ≥5 was significantly associated with adverse clinical features, including advanced-stage disease (P=0.021), elevated lactate dehydrogenase (P=0.002), ECOG performance status ≥2 (P=0.021), higher IPI (P=0.015) and higher NCCN-IPI scores (P=0.032). Patients with CONUT ≥5 had significantly inferior OS (log-rank P=0.001) and PFS (log-rank P=0.003) compared with those with CONUT <5. Similar findings were observed in the low/low-intermediate IPI subgroup. In the multivariate analysis, advanced-stage disease (P=0.036) and a CONUT score ≥5 (P=0.042) remained independent predictors of OS. These findings indicate that a high pre-treatment CONUT score is associated with adverse baseline characteristics and predicts inferior survival outcomes in patients with DLBCL. Given its simplicity, low cost and availability in routine clinical practice, the CONUT score may serve as a useful adjunct to established prognostic indices, although prospective validation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.